Armata Pharmaceuticals Inc.

4.29-0.3000-6.54%Vol 37.55K1Y Perf 18.28%
Jun 14th, 2021 16:00 DELAYED
BID4.17 ASK4.38
Open4.78 Previous Close4.59
Pre-Market- After-Market-
 - -  - -%
Target Price
7.75 
Analyst Rating
— — 0.00
Potential %
80.65 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.42
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap106.99M 
Earnings Rating
Price Range Ratio 52W %
21.84 
Earnings Date
13th May 2021

Today's Price Range

4.214.79

52W Range

2.5610.48

5 Year PE Ratio Range

-0.9000-0.3000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
6.19%
1 Month
7.52%
3 Months
-22.56%
6 Months
61.89%
1 Year
18.28%
3 Years
-75.68%
5 Years
-98.04%
10 Years
-99.72%

TickerPriceChg.Chg.%
ARMP4.29-0.3000-6.54
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
4.70
4.80
0.24
0.39
-41.60
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-2 681.30
-2 547.60
-
-
RevenueValueIndustryS&P 500US Markets
823.00K
0.03
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.28-0.273.57
Q04 2020--0.36-
Q03 2020-0.17-0.31-82.35
Q02 2020-0.23-0.26-13.04
Q01 2020-0.35-0.49-40.00
Q04 2019-0.76-0.4836.84
Q03 2019-0.38-0.73-92.11
Q02 2019-0.29-0.69-137.93
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.28
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume37.55K
Shares Outstanding24.94M
Trades Count182
Dollar Volume203.77K
Avg. Volume34.11K
Avg. Weekly Volume13.14K
Avg. Monthly Volume6.65K
Avg. Quarterly Volume14.70K

Armata Pharmaceuticals Inc. (AMEX: ARMP) stock closed at 4.29 per share at the end of the most recent trading day (a -6.54% change compared to the prior day closing price) with a volume of 37.55K shares and market capitalization of 106.99M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 62 people. Armata Pharmaceuticals Inc. CEO is Todd R. Patrick.

The one-year performance of Armata Pharmaceuticals Inc. stock is 18.28%, while year-to-date (YTD) performance is 43.72%. ARMP stock has a five-year performance of -98.04%. Its 52-week range is between 2.56 and 10.48, which gives ARMP stock a 52-week price range ratio of 21.84%

Armata Pharmaceuticals Inc. currently has a PE ratio of -3.80, a price-to-book (PB) ratio of 3.37, a price-to-sale (PS) ratio of 130.01, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.31%, a ROC of -53.14% and a ROE of -64.91%. The company’s profit margin is -%, its EBITDA margin is -2 547.60%, and its revenue ttm is $823.00 Thousand , which makes it $0.03 revenue per share.

Of the last four earnings reports from Armata Pharmaceuticals Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.28 for the next earnings report. Armata Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Armata Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Armata Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Armata Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Armata Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.54, ATR14 : 0.28, CCI20 : 134.11, Chaikin Money Flow : -0.18, MACD : 0.01, Money Flow Index : 35.17, ROC : 2.39, RSI : 52.30, STOCH (14,3) : 43.82, STOCH RSI : 0.47, UO : 40.34, Williams %R : -56.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Armata Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a clinical-stage biotechnology company focused on improving human health through the development of novel natural and synthetic bacteriophage-based therapies to treat multidrug-resistant bacterial infections and preventable infectious diseases of the microbiome. The company is developing and advancing lead clinical phage candidate for Pseudomonas aeruginosa (P. aeruginosa), AP-PA02. It is also focused on developing a phage product candidate for Staphylococcus aureus (S. aureus) for the treatment of S. aureus bacteremia, AP-SA02.

CEO: Todd R. Patrick

Telephone: +1 858 829-0829

Address: 4503 Glencoe Avenue, Marina del Rey 90292, CA, US

Number of employees: 62

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

100%0%

Bearish Bullish

100%0%

News

Stocktwits